| scholarly article | Q13442814 |
| P50 | author | Andrea Sboner | Q42869291 |
| Scott T Tagawa | Q57622116 | ||
| Vincenza Conteduca | Q64495656 | ||
| Panagiotis J Vlachostergios | Q89611273 | ||
| Megan Slade | Q90008206 | ||
| Michael Sigouros | Q90008225 | ||
| Ryan Dittamore | Q90008239 | ||
| P2093 | author name string | David M Nanus | |
| Himisha Beltran | |||
| Olivier Elemento | |||
| Juan Miguel Mosquera | |||
| Rohan Bareja | |||
| Sheng-Yu Ku | |||
| Luisa Fernandez | |||
| Judy Hess | |||
| Loredana Puca | |||
| P2860 | cites work | Cancer statistics, 2019 | Q90941571 |
| Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients | Q91583263 | ||
| Biological Evolution of Castration-resistant Prostate Cancer | Q91648775 | ||
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial | Q91733148 | ||
| Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents | Q24297639 | ||
| DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 | ||
| Schlafen, a new family of growth regulatory genes that affect thymocyte development | Q28592251 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 | ||
| Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial | Q33386511 | ||
| RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. | Q34494714 | ||
| Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. | Q35861427 | ||
| SLFN11 inhibits checkpoint maintenance and homologous recombination repair | Q35866775 | ||
| Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs | Q36772043 | ||
| Platinum-based chemotherapy for variant castrate-resistant prostate cancer | Q36977870 | ||
| Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | Q37179254 | ||
| Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer | Q37550588 | ||
| Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition | Q37684589 | ||
| Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, | Q38370247 | ||
| Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care | Q38637891 | ||
| Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer | Q38768101 | ||
| Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. | Q38800044 | ||
| Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers | Q39051337 | ||
| Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. | Q40336402 | ||
| PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. | Q40640808 | ||
| The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer | Q41566518 | ||
| Proposed morphologic classification of prostate cancer with neuroendocrine differentiation | Q41994427 | ||
| Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer | Q42704874 | ||
| Platinum sensitivity in metastatic prostate cancer: does histology matter? | Q47195375 | ||
| The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. | Q47347786 | ||
| EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer | Q48325256 | ||
| Chemotherapy for Small Cell Carcinoma of Prostatic Origin | Q48525082 | ||
| Patient derived organoids to model rare prostate cancer phenotypes. | Q55367999 | ||
| Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency | Q57814257 | ||
| Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer | Q64073046 | ||
| Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. | Q64980716 | ||
| Clinical features of neuroendocrine prostate cancer | Q90124919 | ||
| Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer | Q90583994 | ||
| Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis | Q90858658 | ||
| P577 | publication date | 2020-03-03 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy |
| Q99611471 | Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer | cites work | P2860 |
Search more.